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Abstract The principal goal of the present study was to deter- 
mine the subceHular content of GLUT4 in diabetic rat muscle, 
and to test the hypothesis that a reduced abundance of the trans- 
porter protein in transverse tubules is responsible for impaired 
glucose utilization in that tissue. GLUT4 protein levels were 
measured in hindlimb muscle homogenates as well as in subcellu- 
lar membrane fractions enriched with either plasma membranes, 
transverse tubules, or GLUT4-containing intracellular mem- 
branes from control and diabetic (streptozotocin-induced) rats. 
GLUT4 protein contents in diabetic muscle homogenates was 
reduced by 30% as compared to control rats. Subcellular fraction- 
ation experiments revealed that GLUT4 contents in transverse 
tubules-enriched fractions was markedly decreased (by 55-60%) 
in skeletal muscle of diabetic animals whereas no significant 
reductions in GLUT4 abundance was observed in the plasma 
membrane fraction. Moreover, GLUT4 was markedly depleted 
(by 45%) in the GLUT4-enriched intracellular membrane frac- 
tion. These results indicate that GLUT4 is markedly depleted in 
both the intracellular pool and in the cell surface membranes in 
muscle of STZ-diabetic rats. Most strikingly, this study demon- 
strates that transverse tubules and not the plasma membrane are 
the main sites of cell surface GLUT4 depletion in diabetic muscle. 
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I. Introduction 
Glucose transport accross the cell surface is believed to be 
the rate-limiting step for muscle glucose disposal both in nor- 
mal and diabetic individuals [1,2]. In skeletal muscle, the trans- 
port of glucose is predominantly mediated by the GLUT4 glu- 
cose transporter. It is well documented that insulin acutely 
stimulates glucose transport by inducing the translocation of 
GLUT4 transporters from tubulo-vesicular intracellular struc- 
tures to the plasma membrane [3-6]. However, more recent 
studies have shown that the GLUT4 glucose transporter is also 
localized to transverse tubules in rat skeletal muscle [6-9]. The 
transverse tubules are deep invaginations of the plasma mem- 
brane that are involved in excitation-contraction c upling in 
skeletal muscle. Moreover, we have previously reported that 
insulin induces the translocation of GLUT4 to both the trans- 
verse tubules and the plasma membrane in rat skeletal muscle 
[9]. These studies, combined with the fact that transverse tu- 
bules constitute the largest (>60%) area of the cell surface in 
muscle cells [10,11], led us to propose that these tubular struc- 
tures significantly contribute to the entry of glucose into myofi- 
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bers, both in the basal and stimulated conditions. This hypoth- 
esis was recently confirmed by Dudek et al. [12] who found that 
insulin increases cell surface photolabelled GLUT4 trans- 
porters to the transverse tubules using an autoradiographic 
method. 
Skeletal muscle glucose utilization is decreased in both insu- 
lin-dependent (IDDM) and non-insulin-dependent diabetes 
mellitus (NIDDM) (see [13] for a review). A defective xpres- 
sion or regulation of GLUT4 translocation is thought to be 
responsible for the defect in muscle glucose disposal. It has been 
reported that GLUT4 protein and mRNA levels are decreased 
in skeletal muscle of several rodent models of both genetically 
and experimentally induced diabetes [14-17]. In contrast, sev- 
eral studies have shown that GLUT4 expression (GLUT4 
mRNA and protein) is not reduced in skeletal muscle of IDDM 
and NIDDM individuals as compared to normal subjects [18- 
22] with the exception of one study with severely obese type II 
diabetic individuals [23]. However, it may be possible that 
GLUT4 protein abundance in human muscle may be specifi- 
cally decreased in the cell surface membranes, where glucose 
transport akes place. Indeed, it has been reported that the 
reduction in GLUT4 content is more pronounced in isolated 
plasma membranes than in total membranes in diabetic rat 
models of IDDM and NIDDM [17,24]. Recently, two groups 
have specifically looked at this possibility in human muscle 
from NIDDM subjects. Whereas Vogt et al. [25] found a 40- 
50% decrease in GLUT4 in their plasma membrane fraction, 
Lund et al. [26] reported no differences in plasma membrane 
GLUT4 content between muscles of control and diabetic indi- 
viduals. However, the possibility that GLUT4 is depleted in 
muscle transverse tubules of diabetic animals or IDDM and 
NIDDM subjects remains to be investigated. 
The principal goal of the present study was to determine 
whether GLUT4 content is reduced in isolated transverse tu- 
bules from diabetic skeletal muscle, using the streptozotocin 
(STZ)-treated rat as a model of diabetes. To do so, we have 
used a novel membrane fractionation procedure that allows the 
simultaneous i olation of plasma membranes and transverse 
tubules in distinct subcellular fractions from the same muscle 
sample. 
2. Materials and methods 
2.1. Animals 
Male Sprague-Dawley rats (Charles River, Montreal) weighing- 200 
g were injected i.p. with 65 mg/kg of STZ (Sigma) freshly dissolved in 
20 mM citrate buffer (pH 4.5). The control group was injected with 
citrate buffer alone. Tail vein glucose levels were monitored on a daily 
basis with a glucometer (One touch basic, Lifescan) and only rats 
presenting lycemia ---12 mM were considered iabetic and used in the 
following experiments. Seven days after STZ injection, diabetic and 
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control rats were fasted for 6 h, sacrificed and hindlimb muscles (soleus, 
plantaris, tibialis, gastrocnemius and quadriceps) were rapidly excised, 
cleaned of extraneous tissues and frozen in liquid nitrogen. The muscles 
were kept at -80°C until use for membrane preparation. Whole blood 
was kept to determine serum glucose and insulin levels using a glucose 
analyser (Beckman, model 2300 StatPlus) and by RIA using a commer- 
cial kit (Incstar, Stillwater, MN), respectively. 
2.2. Subcellular membrane fractionation 
Plasma membranes (PM), transverse tubules (TT1 and TT2) and 
intracellular membranes (L-IM) were isolated by subcellular f actiona- 
tion using a procedure recently developed in our laboratory [27] and 
partly based on previous methods [4,5,9]. This new protocol allows the 
simultaneous isolation of plasma membranes and transverse tubules in 
distinct fractions from the same original muscle sample. Furthermore, 
as shown in the present study, the procedure yields a novel intracellular 
membrane fraction markedly enriched with GLUT4 but devoid of 
markers for plasma membranes or transverse tubules (see Section 3). 
Hindlimb muscles (~9 g) were minced in buffer A (10 mM NaHCO3, 
pH 7.0, 0.25 M sucrose, 5 mM NAN3, 100/IM phenylmethylsulfon- 
ylfluoride). At this point, a sample was taken and homogenized athigh 
speed and was used as the 'homogenate' fraction. The minced muscles 
were homogenized twice using a Polytron equipped with a PT20 probe 
and a Kinematica speed control (Brinkman Instruments) at a precise 
low setting of 5.0 for 5 s. The resulting homogenate was centrifuged at 
1300xg for 10 rain. The 1300xg supernatant was centrifuged at 
9000xg for 10 rain and then at 190,000xg for 1 h. The 190,000 xg  
pellet was resuspended in buffer A and applied on discontinuous su- 
crose gradients (25, 32 and 35%, w/w) and centrifuged at 150,000 x g 
for 16 h. Membranes at the sample/25% [plasma membranes (PM)] and 
32135% [transverse tubules (TT1)] interphases were recovered, diluted 
with sucrose-free buffer A and centrifuged at 190,000 x g for I h. 
The pellet from the above 1300 x g spin was resuspended in buffer 
B (0.5 M LiBr, 50 mM tris, pH 8.5) and stirred for 4 h. The LiBr-treated 
membranes were centrifuged first at 1200 x g for 5 rain and then at 
10,000 ×g for 30 min and again at 30,000 xg for 1 h. The pellet was 
resuspended in buffer C (0.15 M KC1, 5 mM MgSO4, 20 mM HEPES, 
pH 6.8), applied on 10, 27 and 35% discontinuous sucrose gradients 
(w/w) and centrifuged at 150,000 x g for 16 h. Membranes at the 27/35% 
interphase [(transverse tubules (TT2)] were recovered. The supernatant 
of the 30,000 x g spin was used to isolate the intracellular membrane 
fraction (L-IM) as follows. It was centrifuged at 190,000 x g for 1 h and 
the resulting pellet was resuspended in buffer A. The resuspended 
membranes were applied on a 10140% discontinuous sucrose gradients 
and centrifuged at 150,000xg for 16 h. Membranes at the 10/40% 
interphase [(intracellular membranes (L-IM)] were collected from the 
gradients, diluted with sucrose-free buffer A and were centrifuged at 
190,000 x g for I h. All fractions were resuspended in buffer A and used 
fresh for enzymatic activity measurements or kept at -80°C until used 
for Western blot analysis. 5'-Nucleotidase activity in the isolated mem- 
brane fractions was measured as previously described [28]. 
2.3. Western blot analysis and antibodies 
Membranes (10 p g of proteins unless otherwise indicated) were sub- 
jected to SDS-PAGE on a 7.5% polyacrylamide gel as described by 
Laemmli [29], and Western blotting was performed as previously de- 
scribed [5]. 
Polyclonal antibodies against the GLUTI and GLUT4 glucose trans- 
porters were purchased from East Acres Biologicals (Southbridge, 
MA). The monoclonal antibody llF7 generated against he alphal- 
DHPr was kindly supplied by Dr. K. Campbell (University of Iowa). 
The monoclonal ntibody against the ~I-Na/K-ATPase was a kind gift 
from Dr. K. Sweadner (Massachusetts General Hospital). 
3. Results 
Rats injected with streptozotocin were clearly diabetic after 
7 days, as evidenced by the presence of fasting hyperglycemia 
(1.9-fold over control) and hypoinsulinemia as compared to 
citrate-injected animals (Table 1). As expected, diabetic animals 
gained less weight than controls and consequently, hindl imb 
muscle weights were slightly reduced after one week of diabetes 
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Fig. 1. GLUT4 protein contents in muscle homogenates from control 
and STZ-diabetic rats. The figure shows GLUT4 protein levels in mus- 
cles of 5 control and 5 diabetic rats. A molecular weight standard is 
shown on the left. Homogenates of mixed hindlimb muscles were pre- 
pared and Western blot analysis was performed using 30 pg of proteins. 
Following an overnight incubation at 4°C with primary antibodies, 
immunoblots were incubated with either anti-mouse or anti-rabbit m- 
munoglobulin G conjugated to horseradish peroxidase (Amersham). 
Immunoreactive bands were detected by the enhanced chemilumines- 
cence method. Autoradiographs were quantified by laser scanning den- 
sitometry using the 'Biolmage-Visage 110S' software from Millipore 
(Ann Arbor). 
(Table 1). However, this had no effect on the membrane yields 
of the various fractions, as indicated in Table 2. 
The effect of STZ-diabetes on GLUT4 protein contents in 
skeletal muscle homogenates i  shown in Fig. 1. GLUT4 was 
detected as a single band migrating at 4546 kDa in both con- 
trol and diabetic rat samples. Muscle total GLUT4 content was 
reduced (by 30%) in muscle of diabetic rats as compared to 
controls (rel. densit, units control vs. diabetic samples: 126 + 7 
vs. 88 + 6, n = 7, P < 0.01). In contrast, the relative amounts 
of DHPr,  a transverse tubule-specific protein, were not differ- 
ent between control and diabetic rat homogenates (data not 
shown). 
We next examined GLUT4 membrane distribution and con- 
tents in isolated membrane fractions. Membrane fractions were 
first characterized using 5'-nucleotidase activity (Table 2) and 
the immunologic detection of markers of both the plasma mem- 
brane (~I-Na/K-ATPase and GLUT1)  and the transverse 
tubules (DHPr)  (Fig. 2, Table 2). Neither the diabetic state nor 
the minor differences in muscle weight significantly affected 
5'-nucleotidase activity in these membrane fractions (Table 2). 
As expected, the enzyme activity was mostly abundant  in the 
PM fraction, confirming that this fraction is enriched with 
plasma membrane vesicles. The enzyme was also detected in 
TT1 and TT2 fractions but the activities were much lower and 
not very different than that measured in homogenates (~10 
pmol/mg/min). Furthermore, 5'-nucleotidase was not detecta- 
ble in the LiBr-released intracellular membrane fraction 
(L-IM), at least when using up to 40pg of proteins in the assay. 
However, in preliminary experiments using larger amounts of 
muscle from control rats, we could detect some activity using 
60-70/.tg of L- IM membrane proteins. This activity was lower 
Table 1 
Physiological parameters of control and STZ-diabetic rats 
Control STZ-diabetie 
Initial body weight (g) 205 + 1 208 _+ 3 
Final body weight (g) 275 + 2 221 _+ 7** 
Body weight gain (g) 70 _+ 2 13 _+ 7** 
Muscle weight (g) 9.83 + 0.75 7.60 + 0.48* 
Fasting glycemia (mM) 8.44 + 0.13 15.87 _+ 3.86* 
Fasting insulinemia (nM) 0.95 + 0.24 0.25 -+ 0.06** 
Data are mean + S.E. of seven rats in each group. 
*P < 0.05, **P < 0.0l as analysed by Student's t-test for unpaired com- 
parisons. 
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Fig. 2. Subcellular distribution of plasma membrane and transverse 
tubule markers in isolated membrane fractions and effects of STZ- 
diabetes. Fractions enriched with either plasma membranes, transverse 
tubules, or intracellular membranes were isolated from muscles of con- 
trol (C) and diabetic (D) rats as described in Section 2. The relative 
contents of DHPr, ~I-Na/K-ATPase and GLUT1 proteins were as- 
sessed by Western blotting using specific antibodies ( ee legend of Fig. 
1). Mean values from seven individual experiments are shown in Table 
2. Molecular weight standards are shown on the left. 
or similar to homogenates confirming that plasma membranes 
were not enriched in that fraction (data not shown). We have 
also verified that LiBr treatment did not interfere with the 
enzyme assay by incubating membranes with or without 0.5 M 
LiBr (buffer B) for 4 h, followed by assessment of 5'-nucleo- 
tidase activity. No differences were observed between LiBr- 
treated and untreated membrane samples (data not shown). 
The membrane distribution and levels of the cd-subunit of 
the Na/K-ATPase, a plasma membrane marker [5], and of the 
DHPr, a transverse tubule marker [9], are shown in Fig. 2. The 
cd-Na/K-ATPase was mainly present in the PM fraction, in 
agreement with the enrichment in 5'-nucleotidase activity in 
that fraction. Lower, but detectable vels of the subunit could 
also be detected in TTI but not in TT2 or L-IM fractions. In 
sharp contrast, he DHPr was mainly detected in TT1 and TT2 
fractions and could be barely detected in the PM or the L-IM 
fraction. The latter fraction was devoid of markers of either 
plasma membrane or transverse tubules, thus confirming that 
vesicles of intracellular origin were isolated in that fraction. 
Moreover, the GLUT1 glucose transporter was only detected 
in the plasma membrane fraction (Fig. 2), confirming previous 
immunoblotting and immunocytochemical studies [5,30]. Im- 
portantly, STZ-diabetes had no significant effects on any of 
these proteins (see mean values in Table 2), indicating that 
diabetes did not lead to non-specific changes in the recovery of 
either plasma membranes or transverse tubules in the above 
fractions. 
A representative immunoblot showing GLUT4 protein 
amounts in surface membranes and intracellular membranes 
isolated from muscle of STZ-diabetic and control rats is de- 
picted in Fig. 3A. The mean values from seven individual exper- 
iments are presented in Fig. 3B. GLUT4 was markedly en- 
riched in the intracellular membrane fraction (L-IM), confirm- 
ing that it represents a GLUT4-enriched intracellular pool. 
When compared to the plasma membrane fraction, GLUT4 
abundance was slightly higher in TTI transverse tubule fraction 
and significantly greater in the TT2 fraction in both control and 
diabetic muscles. Remarkably, GLUT4 protein levels were 
markedly decreased in transverse tubule fractions (by 55-60%) 
of diabetic rats as compared to non-diabetic controls (Fig. 
3A,B). The GLUT4-enriched intracellular f action was also 
markedly depleted (by 45%) of GLUT4 in the diabetic state. On 
the other hand, GLUT4 abundance in the plasma membrane 
fraction was slightly but not significantly reduced. In average, 
we observed a small 20% reduction in GLUT4 content in that 
fraction. The effect of diabetes on GLUT4 protein levels was 
maintained when data were expressed per total fraction since 
membrane yields were not affected by the diabetic state (Table 
2) (data not shown). 
4. Discussion 
It has been shown that basal glucose transport is decreased 
in per±used hindlimb muscles of STZ-diabetic rats [24]. It has 
also been reported that GLUT4 is decreased in the plasma 
membrane of STZ-diabetic rats [24,31]. However, when both 
hindlimb glucose uptake and GLUT4 abundance inthe plasma 
membrane were compared in the same animals, the reduction 
in plasma membrane GLUT4 content was found to be very 
small (-18%) as compared to the impairment in basal glucose 
uptake (-70%) in the hindlimbs [24]. In the present study, we 
have also observed a slight, albeit not significant, 20% reduc- 
tion in plasma membrane GLUT4 abundance. 
More importantly, GLUT4 protein levels in transverse tu- 
bules, the main area of the muscle cell surface envelope, has 
never been examined in skeletal muscle of diabetic rats. The 
results of the present study demonstrate for the first time that 
transverse tubules are markedly depleted of GLUT4 trans- 
porters in skeletal muscle of STZ-diabetic rats. GLUT4 was 
decreased by > 50% in both fractions enriched with transverse 
Table 2 
Enzymatic and immunologic characterization f isolated membranes and effects of STZ-diabetes 
Fractions Yield 5' AMP ~I-Na/K DHPr GLUT1 
(/zg/g musc le )  (nmol/mg/min) (rel. units) (rel. units) (rel. units) 
PM CTL 28 + 1 165.8 _+ 22.9 1606 + 428 73 + 26 135 + 15 
STZ 30 + 4 175.0 _+ 11.4 1806 +_ 354 88 ± 17 129 + 28 
TT1 CTL 197 + 11 40.6 + 4.3 280 + 83 879 + 183 ND 
STZ 267 + 30 38.9 + 6.9 327 + 69 825 ± 185 ND 
TT2 CTL 77 + 26 15.5 + 5.8 ND 1044 ± 399 ND 
STZ 92 ± 25 15.7 ± 5.6 ND 884 ± 224 ND 
L-IM CTL 35 ± 11 ND ND 305 ± 57 ND 
STZ 35 ± 12 ND ND 268 ± 46 ND 
Data are mean +_ S.E. of seven membrane preparations in each experimental group. 
PM, plasma membranes; TT, transverse tubules; L-IM, LiBr-released intracellular membranes; ND, non-detectable. 
No significant differences were observed between control and STZ-diabetic animals. 
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Fig. 3. GLUT4 protein levels in plasma membrane (PM), transverse 
tubules (TT1 and TT2) and intracellular membrane (L-IM) fractions 
isolated from muscles of control (C) and diabetic (D) rats. (A) Repre- 
sentative immunoblot, (B) mean + S.E. of seven individual membrane 
preparations, each performed with one control and one diabetic rat. 
Scanning data are expressed relative to GLUT4 levels in crude muscle 
membrane samples that were run on parallel on every gels. *P < 0.05, 
**P < 0.01 as analysed by Student's t test for unpaired comparisons. 
tubules whereas the transporter abundance was not signifi- 
cantly reduced in the plasma membrane fraction (Fig. 3). On 
the other hand, GLUT1 is not present in the transverse tubules 
and its content in the plasma membranes i  not changed in 
STZ-diabetic rats. Thus, our data suggest hat the defective 
basal glucose uptake in muscle of STZ-diabetic animals is 
mainly explained by a decreased number of GLUT4 operating 
in the transverse tubules. However, direct experimental evi- 
dence will only come with measurements of glucose transport 
fluxes in isolated transverse tubules vesicles. 
In agreement with previous tudies [24,31], GLUT4 was also 
found to be significantly depleted from the intracellular mem- 
brane fraction in STZ-diabetic rats. This fraction is markedly 
enriched with GLUT4 but devoid of markers of both plasma 
membranes and transverse tubules, even when compared to 
muscle homogenates. We have recently shown that this intra- 
cellular fraction represents an insulin-responsive ntracellular 
pool from which GLUT4 is translocated to both the plasma 
membrane and the transverse tubules in non-diabetic rats [27]. 
Whether the translocation of GLUT4 from this GLUT4-de- 
pleted intracellular f action to either plasma membranes or 
transverse tubules is impaired in the STZ-diabetic rat model 
remains to be investigated. 
The differences in GLUT4 levels between the two TT frac- 
tions (Fig. 3) despite similar levels of DHPr (Fig. 2, Table 2) 
is intriguing. This difference was seen both in normal and dia- 
betic animals. Transverse tubule membranes recovered in frac- 
tion TT1 could be easily dissociated from the muscle bulk by 
mild homogenization whereas TT2 contains transverse tubule 
vesicles that were released using LiBr. Another difference is 
that the el-subunit of the Na/K-ATPase could be detected in 
TT1 but not TT2 fractions. It has been previously demon- 
strated that transverse tubules are not always joined to the SR 
in mammalian skeletal muscle [32]. It is therefore possible that 
TT1 membranes are non-junctional nd, thus, derived from 
tubules not joined to the cisternal SR, thereby explaining their 
release by mild homogenization. On the other hand, TT2 may 
contain junctional transverse tubules that can only be released 
by high-salt reatment. The non-junctional tubules would not 
be involved in the excitation-contraction coupling but still con- 
tribute to increase the availability, transport and utilization of 
extracellular substrates such as glucose deep into the muscle 
cells. 
In summary, the results of the present study show that 
GLUT4 protein content is markedly depleted in both the intra- 
cellular pool and in the cell surface membranes in muscle of 
STZ-diabetic rats. Furthermore, this study provides the first 
experimental evidence that cell surface GLUT4 depletion is 
much greater in the transverse tubules than in the plasma mem- 
brane in skeletal muscle of STZ-diabetic rats. 
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